fax: (30) 210-6972974
Outcome of hepatitis B e antigen–negative chronic hepatitis B on long-term nucleos(t)ide analog therapy starting with lamivudine†
Article first published online: 16 JUN 2005
Copyright © 2005 American Association for the Study of Liver Diseases
Volume 42, Issue 1, pages 121–129, July 2005
How to Cite
Papatheodoridis, G. V., Dimou, E., Dimakopoulos, K., Manolakopoulos, S., Rapti, I., Kitis, G., Tzourmakliotis, D., Manesis, E. and Hadziyannis, S. J. (2005), Outcome of hepatitis B e antigen–negative chronic hepatitis B on long-term nucleos(t)ide analog therapy starting with lamivudine. Hepatology, 42: 121–129. doi: 10.1002/hep.20760
Potential conflict of interest: Dr. Manolakopoulos is a consultant for Gilead. Dr. Kitis is a consultant for and has received a research grant from Gilead. Dr. Papatheodoridis is on the advisory board for Roche and is the principal investigator in clinical trials for Idenix. Dr. Manesis has received a research grant from Schering-Plough. Dr. Hadziyannis is a consultant, on the speakers' bureau, and on the advisory board for Gilead, Roche, and Bristol-Myers Squibb and has received research grants from Gilead and Roche.
- Issue published online: 16 JUN 2005
- Article first published online: 16 JUN 2005
- Manuscript Accepted: 19 APR 2005
- Manuscript Received: 8 FEB 2005
- 1Hepatitis B e antigen negative chronic hepatitis B: From clinical recognition to pathogenesis and treatment. Vir Hep Rev 1995; 1: 7–36..
- 18Clinical course of lamivudine monotherapy in patients with decompensated cirrhosis due to HBeAg negative chronic HBV infection. Am J Gastroenterol 2004; 99: 57–63., , , , , , et al.Direct Link: